Rhodes Pharmaceuticals, L.P. clinical trials
Acquired by Knoa Pharma, May 1, 2026 · source ↗
The registry lists 11 studies whose lead sponsor is Rhodes Pharmaceuticals, L.P.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 22, 2023.
Before and after it joined Knoa Pharma
- First submitted before Rhodes Pharmaceuticals, L.P. became part of Knoa Pharma
- 11
- First submitted after Rhodes Pharmaceuticals, L.P. became part of Knoa Pharma
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Rhodes Pharmaceuticals, L.P.11 studies
Something wrong with this grouping? Tell us on the Knoa Pharma page.
Studies
Recruiting first, then most recently updated. Showing 11 of 11. All Knoa Pharma studies →
- Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHDCompletedNCT01239030Phase 3
Sponsor listed in the registry: Rhodes Pharmaceuticals, L.P. · First submitted before Rhodes Pharmaceuticals, L.P. became part of Knoa Pharma
- A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHDCompletedNCT02683265Phase 4
Sponsor listed in the registry: Rhodes Pharmaceuticals, L.P. · First submitted before Rhodes Pharmaceuticals, L.P. became part of Knoa Pharma
- Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom SettingCompletedNCT01269463Phase 3
Sponsor listed in the registry: Rhodes Pharmaceuticals, L.P. · First submitted before Rhodes Pharmaceuticals, L.P. became part of Knoa Pharma
- Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHDCompletedNCT02470234Phase 4
Sponsor listed in the registry: Rhodes Pharmaceuticals, L.P. · First submitted before Rhodes Pharmaceuticals, L.P. became part of Knoa Pharma
- The Efficacy and Safety of PRC-063 in Adult ADHD PatientsCompletedNCT02139124Phase 3
Sponsor listed in the registry: Rhodes Pharmaceuticals, L.P. · First submitted before Rhodes Pharmaceuticals, L.P. became part of Knoa Pharma
- A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHDCompletedNCT02555150Phase 3
Sponsor listed in the registry: Rhodes Pharmaceuticals, L.P. · First submitted before Rhodes Pharmaceuticals, L.P. became part of Knoa Pharma
- A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHDStatus unknownNCT02677519Phase 4
Sponsor listed in the registry: Rhodes Pharmaceuticals, L.P. · First submitted before Rhodes Pharmaceuticals, L.P. became part of Knoa Pharma
- PRC-063 in an ADULT Workplace EnvironmentCompletedNCT02225639Phase 3
Sponsor listed in the registry: Rhodes Pharmaceuticals, L.P. · First submitted before Rhodes Pharmaceuticals, L.P. became part of Knoa Pharma
- Long-Term Safety of PRC-063 in Adolescents and Adults With ADHDCompletedNCT02168127Phase 3
Sponsor listed in the registry: Rhodes Pharmaceuticals, L.P. · First submitted before Rhodes Pharmaceuticals, L.P. became part of Knoa Pharma
- PRC-063 in Adolescent ADHDCompletedNCT02139111Phase 3
Sponsor listed in the registry: Rhodes Pharmaceuticals, L.P. · First submitted before Rhodes Pharmaceuticals, L.P. became part of Knoa Pharma
- Safety and Efficacy of PG101 for Dry Eye SyndromeCompletedNCT02078661Phase 1/2
Sponsor listed in the registry: Rhodes Pharmaceuticals, L.P. · First submitted before Rhodes Pharmaceuticals, L.P. became part of Knoa Pharma